COMPASS Pathways Reports $137.7 Million Net Loss in Q3 2025, Progresses in Clinical Trials

COMPASS Pathways plc has reported significant financial results for the third quarter of 2025, revealing a net loss of $137.7 million, compared to a loss of $38.5 million in the same period last year. For the nine months ending September 30, 2025, the company recorded a net loss of $194 million, up from $111.8 million in the prior year. The increase in losses is attributed primarily to a fair value change of warrant liabilities amounting to $101.3 million, which was not present in the previous year. Total operating expenses for the quarter were $40.5 million, a decrease from $47.9 million in Q3 2024, driven by reduced research and development costs.

In terms of operational metrics, COMPASS Pathways has made notable progress in its clinical trials for its investigational COMP360 psilocybin treatment, particularly for treatment-resistant depression (TRD). The company has completed enrollment for its second pivotal trial, COMP006, with 585 participants, and has reported positive preliminary results from its first pivotal trial, COMP005. The company is also exploring additional indications, including post-traumatic stress disorder (PTSD), where it has completed a Phase 2 study demonstrating safety and tolerability.

The company’s cash position has improved, with cash and cash equivalents totaling $185.9 million as of September 30, 2025, compared to $165.1 million at the end of 2024. This increase is largely due to financing activities, including proceeds from the issuance of ordinary shares and warrants, which generated $140.4 million in the first nine months of 2025. The company anticipates that its current cash reserves will be sufficient to fund operations into 2027, although it acknowledges the need for additional capital to support ongoing clinical trials and potential commercialization efforts.

Strategically, COMPASS Pathways has engaged in various financing activities, including a loan agreement with Hercules Capital, which allows for borrowings of up to $50 million. The company has also entered into a new sales agreement for its at-the-market offering program, enabling it to issue and sell up to $150 million of American Depositary Shares (ADSs). As of now, the company has not sold any ADSs under this new agreement, but it remains a potential source of future capital.

Looking ahead, COMPASS Pathways is focused on advancing its clinical programs and preparing for regulatory submissions. The company plans to submit a proposal for a rolling submission of a new drug application (NDA) for COMP360 to the FDA, with expectations to disclose additional trial data in early 2026. Despite the challenges of operating in a competitive and rapidly evolving market, the company remains committed to its mission of providing innovative treatments for mental health conditions.